Latest Breaking News On - Juvenile arthritis disease activity score - Page 1 : comparemela.com

Early Biologic Initiation Linked to Rapid Improvement of JIA

The findings have implications for insurance rules that require patients to take a DMARD for a minimum period before initiating biologic therapy.

United statesMarinka twiltHarvard medical schoolResearch committeeRheumatology research allianceAmerican college of rheumatologyChildhood arthritisSing ongAlberta childrenMedscape medicalEarly combinationBiologic firstJuvenile arthritis disease activity scoreAmerican college

Multiple Social Disadvantages Worsen Kids Rheumatic Disease

Two recent studies revealed the compounding effects of negative social determinants of health on worse disease presentation and activity over time.

United statesOhio state universityStacyp ardoinWilliam daniel soulsbyJoycec changRheumatology research allianceOhio state university in columbusUniversity of california san franciscoNational survey of children healthChildhood health assessment questionnaireChildhood arthritisCalifornia san franciscoNationwide childrenNational surveyJuvenile arthritis disease activity scoreReduced childhood

Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis

1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in serious adverse events between the baricitinib and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely

Rating levelJuvenile arthritis disease activity scoreHospitalized adultsBetween decEnthesitis related arthritisJoint painJuvenile idiopathic arthritisJuvenile psoriatic arthritisPediatric rheumatologyPsoriatic arthritisSystemic jiaChronic disease

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Etanercept enbrelJ clin pharmacolPediatr rheumatolVan dijkhuizenChild health questionnairePediatric rheumatology collaborative study groupChildhood health assessment questionnaireAmerican college of rheumatologyInternational leagueRev dis primersRheumatology collaborative studyEnglj medCare resSyst pharmacolExp rheumatolAmerican college

Etanercept Safe, Effective in Real-World Juvenile Psoriatic Arthritis Study

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Colleenk correllRheumatology research allianceAmerican college of rheumatology pediatric responseUniversity of minnesota colleenk correllUniversity of minnesotaChildhood arthritisAmerican collegeRheumatology pediatric responsePedi responseJuvenile arthritis disease activity score